Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share US00973E1029 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 100.00p 85.00p 115.00p 100.00p 100.00p 100.00p 0 06:30:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.4 -2.7 -49.4 - 8.87

Akers Biosciences Share Discussion Threads

Showing 3901 to 3924 of 3925 messages
Chat Pages: 157  156  155  154  153  152  151  150  149  148  147  146  Older
DateSubjectAuthorDiscuss
14/7/2017
13:35
Bill is there to show them the ropes They will need to buy more boardroom chairs ;
norbus
14/7/2017
09:49
Bill J White might be busy. "Mr White is a Certified Fraud Examiner".
mcmather
14/7/2017
09:02
Another "Scheiber" special ; A funding round at 50p
norbus
19/6/2017
08:48
Never mind the well, the water table has sunk
norbus
16/6/2017
16:21
The well must be close to drying?
mcmather
09/6/2017
10:05
A Rabbit a day by the looks of things
norbus
08/6/2017
09:42
Another rabbit gone
norbus
07/6/2017
11:16
It's "Watership Down" all over again. A dark story with a limited happy ending.How many more Rabbits must die before this saga is over? hTTps://www.youtube.com/watch?v=cGyQmH9NZcw
algernon2
07/6/2017
07:18
I repeat, they are in the wrong business and should be breeding rabbits. If this were a Cat, it'd be thoroughly dead by now
norbus
06/6/2017
23:22
That might be his forte; he said last summer that they hoped to have agreements for the PIFA Heparin tests in place with IDNs (Integrated Delivery Networks) by the end of 2016. They got a trial / agreement with GNYHA (300 hospitals) and they appear to have no concerns with the device other than they don't appear interested in buying it; sales of the device in the US were up but by less than 1% in Q1 2017. Cash burn for Q1 averaged $121k per week although that was said to be above average / target for some reason given. There's been no news since the results, albeit, they are scheduled to ship the first batch of Tri-Cholesterol in June 2017....
mcmather
05/6/2017
16:34
Tiddly winks?
norbus
05/6/2017
15:29
Has Gormally hit it out of the park Wally-esque 'yet'?
mcmather
19/5/2017
12:45
Steep drop in share price . Wally might have done better breeding rabbits
norbus
16/5/2017
15:55
'usage' of PIFA HIT in the US increased by "less than 1%"! They're still working on the 'agreement' with GNYHA, Chlamydia won't be till July 2017 at the earliest with the Tri-Cholesterol not shipped until "early June 2017". He's not quite King Wally but the end result is pretty much the same.
mcmather
16/5/2017
15:07
Sunning interest post results. 32 shares traded.
norbus
16/5/2017
15:04
Wally had better look for another milk cow
norbus
16/5/2017
08:13
Wally II? PIFA HIT revenue up just 2.3% on the previous quarter; pre the significant price increase this equates to PIFA HIT product revenue of around $1.2m per year which is about where they were nearly a decade ago... This from the results for 2016; "We continued to see strong evidence during 2016 of growing demand for our PIFA Heparin PF/4 Rapid Assay products. This is reflected in an uplift in sales for these products of 85% in the period. We believe it is a notable achievement to have successfully implemented our evidence-based outcome proposition that supported our pricing for our PIFA Heparin PF/4 Rapid Assay within the market. This fact speaks volumes about our branded flagship offering that has the ability to provide significant savings for hospitals through the implementation of our test for platelet factor four antibodies. Our strategy to focus on integrated delivery networks and group purchasing organizations in the U.S. is gaining traction, as demonstrated in the three-year agreement announced with the GNYHA Services in December 2016 to introduce our tests across their network of over 300 member hospitals and health systems"... 2.3% increase does not inspire confidence in terms of how the product is perceived in the US and which then creates concern re whether others will be compelled / interested to buy the device.
mcmather
15/5/2017
23:35
Interesting day tomorrow; the HIT trial with GNYHA was seemingly given the green light in Jan 2017 following the trial with 5 institutions (which apparently represents just north of a third of the 300 hospitals under GNYHA) and which led to the Puerto Rica 'extension' in April 2017. What will US revenue be for PIFA HIT for Q1 2017?
mcmather
27/4/2017
16:39
Defo not newsworthy but wise to have in place prior to pr campaign and reference to "initially of oxicheck" might be of interest.
mcmather
24/4/2017
16:19
Initial thought is the news is nothing. But when you think about the target market here, the number of homes the programme will be run and women / mobile phones / talking about 'health' / being able to show each other their results on their phones when they meet up, etc??
mcmather
24/4/2017
15:16
News from the USA (not released yet on RNS) - the US price is up above $2: Http://finance.yahoo.com/news/akers-biosciences-updates-akers-wellness-110000264.html "Akers Biosciences Updates on Akers Wellness(TM) Tests April 24, 2017 THOROFARE, NJ--(Marketwired - Apr 24, 2017) - Akers Biosciences, Inc. ( NASDAQ : AKER ) ( AIM : AKR.L ) ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that the Akers Wellness™ app, which enables users to track the results of Akers Wellness™ breath-based tests via their mobile device, has been approved by the Apple App Store and is now available for download on iOS devices. The Akers Wellness™ app has until now only been available for android devices on the Google Play Store. The app works in conjunction with BreathScan Lync™, the new bluetooth-enabled reading device from Akers Wellness™, and disposable breath-based test cartridges, to help promote, track and/or encourage choices related to general health and wellbeing. The iOS compatibility is a significant step in the commercialization of Akers Wellness™ tests due to the dominance of iOS devices in the mobile device market. A key target in the Company's marketing strategy is the multilevel marketing nutraceutical suppliers. The Company believes iOS compatibility is critical to the success in this market and will now rapidly proceed to market to this industry. The first commercialized Akers Wellness™ breath test is BreathScan OxiChek™, the first disposable breath test to rapidly determine levels of oxidative stress in the body by measuring the levels of certain abundant free radicals. Unlike current laboratory testing methods that test only a few free radicals using an invasive blood draw -- and have a turnaround time of 7 to 10 days -- Akers Bio's rapid OxiChek™ test detects a broad spectrum of free radicals contained in a person's exhaled breath in just a few minutes. Frequent use of OxiChek™ may help health practitioners to monitor and adjust their clients' regimen of nutritional supplementation in order to manage oxidative stress -- an indicator of the overall health and wellbeing of a person. A highly successful clinical trial of OxiChek™ carried out in 2016 demonstrated a correlation between OxiChek™ and the standard reference laboratory blood testing method (TBARS) of 99.5%. OxiChek™ is now commercialized and selling through the Company's distributor, Aero-Med, to anti-aging, functional and integrative health and wellness treatment practitioners in the US. The Company is also ramping up marketing initiatives of OxiChek™ to professionals through enhanced e-commerce and social media platforms. In addition to targeting professionals, Akers Wellness™ intends to start marketing OxiChek™ through direct-to-consumer channels this year. This will include a television marketing campaign through the popular Balancing Act national television show on the Lifetime network. Balancing Act is America's premier morning show that introduces positive solutions to busy, on-the-go modern women. Akers Wellness™ has completed filming of the program, which will be aired multiple times on Lifetime this quarter and syndicated to approximately 200 affiliates. This marketing initiative is targeting women aged 25-45 and will potentially reach approximately 98 million households and thousands of online viewers. Raymond F. Akers, Jr. PhD, Vice Chairman of Akers Bio, commented: "We have completed our near-term product offering for the expansive health and wellness and anti-aging industry with the addition of iOS compatibility for the Akers Wellness™ app, which was the last hurdle to what we believe will be a rapid growth curve in revenue for these products. Akers Wellness™ is dedicated to improving the health and wellbeing of its customers and we believe that OxiChek™ will have a significant impact on this goal. We are turning our attention to providing more services to our customers through our app and, in turn, creating secondary revenue generating opportunities. The Company is pleased to be launching enhanced e-commerce and social media platforms around OxiChek™ and is looking forward to the start of our television marketing campaign in the coming weeks." John J. Gormally, Chief Executive Officer of Akers Bio, added: "I am very excited about the advancements in our commercialization strategy for Akers Wellness™ products and look forward to these propelling our sales, initially of OxiChek™, and later our other Akers Wellness™ tests."
rivaldo
20/4/2017
14:02
Best get AKR to take them over then,
norbus
20/4/2017
10:47
I think this could be a 15 bagger within 8 months. ImmuPharma (IMM) Share price 55.6p Market Cap £73m 1) ‘Lupuzor’; for Lupus currently in pivotal Phase 3 trials. 2) All patients now recruited. 3) Results expected Q1 2018. 4) Incremental announcements expected throughout 2017. 5) On FDA’s “fast track” “special protocol” route after strong safety and efficacy in Phase 2, so if IMM adheres to same protocol as Phase 2b and delivers positive results, FDA will approve and not request further trial with different endpoints or outcomes. 6) Potential “multi-billion dollar sales”. 7) Currently 100% owned by IMM. 8) Very little competition, with only one other Lupus drug approved in last 50 years - GSK’s Benlysta reached sales over $400m in 2015, with annual sales predicted at $1bn by 2020. 9) IMM’s Lupuzor already demonstrated in Phase IIb to be safer and more effective than Benlysta, and is expected to have lower pricing. 10) Fully cashed up from £4.1m fund raise in March 2017, enabling it to complete pivotal Phase 3 trials and progress other pipeline projects. Northland Capital has 171p current valuation on IMM. With the blockbuster sales potential, little competition, good Phase 2 and FDA fast track and special protocol status, I personally think it could be £7 to £10 if the Phase 3 results are good in Q1 2018. ----------------------- 14/3/2017 "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug" [i.e. IMM’s Lupuzor] 4 min 40 sec. www.youtube.com/watch?v=M5Af_uSSXTM www.immupharma.org/sites/default/modules/immu/downloads/IMM-presentation-march-2017v2.pdf
money maker1
20/4/2017
10:44
Gormally acted appropriately.You both seem keen to move the discussion onto other things, so best wishes with that and have a great day.
wigwammer
Chat Pages: 157  156  155  154  153  152  151  150  149  148  147  146  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170724 10:51:50